TOP TALENT FROM DIVERSE BACKGROUNDS

Board of Directors

Masayuki Kobayashi
PRESIDENT & REPRESENTATIVE DIRECTOR
Taiho Pharmaceutical Co., Ltd.
In April 2012, Mr. Kobayashi was appointed President & Representative Director of Taiho Pharmaceutical Co. Since 1993, he has taken on various roles at Taiho, working in both clinical research and sales. From 2002 to 2010, Mr. Kobayashi launched Taiho Pharma USA, Inc., as President and CEO of the company. He went on from there to serve as President and CEO of Otsuka America, Inc. from June 2010 to March 2012. Masayuki Kobayashi graduated from Gakushuin University in 1989.
Tim Whitten
President & CEO
Taiho Oncology, Inc.
Timothy Whitten joined Taiho Oncology in 2013 as the Senior Vice President and CCO to build the first commercial business unit for Taiho in the West and to oversee the company’s commercial functions. In 2017, Mr. Whitten was promoted to Senior Vice President and COO, adding human resources and operations of Taiho Pharma Canada, Inc. to his responsibilities. On January 1, 2018, Mr. Whitten was promoted to President, Taiho Oncology, Inc., and given a position on the Taiho Oncology Board of Directors as he assumed leadership responsibility for corporate, commercial and clinical development-related functions at Taiho Oncology. In addition, Mr. Whitten serves as President of Taiho Pharma Canada and holds a seat on the Taiho Pharma Canada Board, as well as having operational responsibility for Taiho Pharma Europe, Ltd. As of April 1, 2018, Mr. Whitten has been named President and CEO of Taiho Oncology, reporting directly to Masayuki Kobayashi, President and Representative Director Pharmaceutical Co., Ltd., headquartered in Tokyo, Japan, following Eric Benn’s retirement as CEO, Taiho Oncology, Inc. Prior to joining Taiho Oncology, Inc., Mr. Whitten served as President and CEO of Transave/lnsmed from 2006 to 2012. During this time, he guided the company’s lead product from the preclinical stage into a global phase 3 program. In 2010, Mr. Whitten took the private company, Transave, into the public marketplace via a business combination with lnsmed. From 2001 to 2006, Mr. Whitten was employed by Pharmacyclics, where he served in various roles, including Senior Vice President, Marketing & Sales, and Business Development. Mr. Whitten spent 17 years at Bristol-Myers Squibb, where he served in various sales, marketing, and strategic planning roles, including Vice President, Marketing, for the U.S. Oncology and Immunology franchise and Vice President, Global Marketing, Oncology, Immunology, and Pulmonary Diseases. Among his accomplishments, including several product launches, he directed the successful introduction of Taxol® into the U.S. oncology market. Mr. Whitten graduated from West Virginia University with a Bachelor of Science in Pharmacy and from the University of Virginia with a Master of Business Administration.

EXECUTIVE LEADERSHIP TEAM

Taiho Oncology executive leadership team members are made up of industry leaders from both Japan and the United States. Each member possesses a deep understanding of the pharmaceutical industry, along with a proven track record in clinical research, product development, sales and marketing, and corporate governance.

Masayuki Kobayashi
PRESIDENT & REPRESENTATIVE DIRECTOR
Taiho Pharmaceutical Co., Ltd.
In April 2012, Mr. Kobayashi was appointed President & Representative Director of Taiho Pharmaceutical Co. Since 1993, he has taken on various roles at Taiho, working in both clinical research and sales. From 2002 to 2010, Mr. Kobayashi launched Taiho Pharma USA, Inc., as President and CEO of the company. He went on from there to serve as President and CEO of Otsuka America, Inc. from June 2010 to March 2012. Masayuki Kobayashi graduated from Gakushuin University in 1989.
Tim Whitten
President & CEO
Taiho Oncology, Inc.
Timothy Whitten joined Taiho Oncology in 2013 as the Senior Vice President and CCO to build the first commercial business unit for Taiho in the West and to oversee the company’s commercial functions. In 2017, Mr. Whitten was promoted to Senior Vice President and COO, adding human resources and operations of Taiho Pharma Canada, Inc. to his responsibilities. On January 1, 2018, Mr. Whitten was promoted to President, Taiho Oncology, Inc., and given a position on the Taiho Oncology Board of Directors as he assumed leadership responsibility for corporate, commercial and clinical development-related functions at Taiho Oncology. In addition, Mr. Whitten serves as President of Taiho Pharma Canada and holds a seat on the Taiho Pharma Canada Board, as well as having operational responsibility for Taiho Pharma Europe, Ltd. As of April 1, 2018, Mr. Whitten has been named President and CEO of Taiho Oncology, reporting directly to Masayuki Kobayashi, President and Representative Director Pharmaceutical Co., Ltd., headquartered in Tokyo, Japan, following Eric Benn’s retirement as CEO, Taiho Oncology, Inc. Prior to joining Taiho Oncology, Inc., Mr. Whitten served as President and CEO of Transave/lnsmed from 2006 to 2012. During this time, he guided the company’s lead product from the preclinical stage into a global phase 3 program. In 2010, Mr. Whitten took the private company, Transave, into the public marketplace via a business combination with lnsmed. From 2001 to 2006, Mr. Whitten was employed by Pharmacyclics, where he served in various roles, including Senior Vice President, Marketing & Sales, and Business Development. Mr. Whitten spent 17 years at Bristol-Myers Squibb, where he served in various sales, marketing, and strategic planning roles, including Vice President, Marketing, for the U.S. Oncology and Immunology franchise and Vice President, Global Marketing, Oncology, Immunology, and Pulmonary Diseases. Among his accomplishments, including several product launches, he directed the successful introduction of Taxol® into the U.S. oncology market. Mr. Whitten graduated from West Virginia University with a Bachelor of Science in Pharmacy and from the University of Virginia with a Master of Business Administration.
Martin J. Birkhofer, M.D.
Senior Vice President and Chief Medical Officer
Taiho Oncology, Inc.
Dr. Martin J. Birkhofer was appointed Taiho Oncology Inc.’s Senior Vice President and Chief Medical Officer on June 19, 2017. As Chief Medical Officer Dr. Birkhofer has responsibility for the Taiho Oncology Development organization, driving clinical development of our pipeline assets in all geographies outside of Asia. In addition his responsibilities include, Regulatory Affairs, Medical Affairs and Pharmacovigilance. Dr. Birkhofer is a Medical Oncologist and accomplished leader in the oncology biopharmaceutical industry with over 28 years of experience encompassing all phases of global clinical research & development with both small molecules and biologics. He spent the bulk of his career at Bristol-Myers Squibb where he held a variety of senior positions in Clinical Development, Clinical Pharmacology, Medical Affairs and Business Development. In addition, he has served as the Chief Medical Officer of a major contract research organization, inVentiv Health Clinical and of several privately held, venture backed biotech companies. Dr. Birkhofer received his M.D. from New York Medical College, Valhalla, New York and then post graduate medical training in Internal Medicine from St. Elizabeth’s Hospital of Boston, Boston, MA and in Hematology/Oncology from Columbia University College of Physicians and Surgeons, NY, NY.
Michael Schick
Senior Vice President, Commercial
Taiho Oncology, Inc.
Michael Schick was promoted to Sr. Vice President, Commercial in April, 2017, taking on responsibility for Market Access and Market Research to create a positive synergy with improved efficiency in Commercial operations and utilization of resources. In May, 2016, Michael was promoted to Sr. Vice President, Sales and Marketing, leading the entire sales, marketing, and sales operations teams. Michael Schick joined Taiho Oncology, Inc. as Vice President, Sales in Marketing in July 2013. Prior to joining the company, Mr. Schick was a self-employed consultant to the pharmaceutical industry from January 2013 to June 2013. Before that, he served various sales and marketing leadership roles at Allos Therapeutics, including Vice President, Sales and Marketing and Vice President of Marketing from July 2009 to October 2012. While at Allos, Mr. Schick was a member of the executive management team that transformed the organization from a development stage biotech to a commercial stage pharmaceutical company. Prior to that, he served as Associate Vice President, Oncology Marketing at ImClone Systems from October 2007 to July 2009, where he was responsible for the Erbitux® (cetuximab injection) franchise across multiple indications. Prior to that, from February 2006 to October 2007, Mr. Schick was Executive Director, Oncology Global Marketing at Amgen Inc., where he was responsible for global marketing activities for Neulasta® (pegfilgrastim) and Aranesp® (darbepoetin alfa injection). From November 2004 to January 2006, Mr. Schick served as Director, Marketing at Pharmacyclics, Inc. Before that, he served in a variety of commercial roles at Bristol-Myers Squibb, including sales, strategic planning, and product management focused on multiple oncology brands, including Taxol® (paclitaxel injection) and Paraplatin® (carboplatin for injection), and the launch of Erbitux for metastatic colorectal cancer. Mr. Schick earned his B.A. from Villanova University.
Nobuyuki Hashimoto
Managing Director, Board Member
Corporate Division, Quality and Reliability Assurance Division
Taiho Pharmaceutical Co., Ltd.
Fabio Benedetti, M.D.
Global Chief Medical Officer
Taiho Pharmaceutical Co., Ltd.
Dr. Fabio Benedetti, MD, was appointed Global Chief Medical Officer in January 2016. Dr. Benedetti has extensive experience in oncology, ranging from medical practice to clinical drug development and medical affairs. Prior to joining the company, he has served in various leadership positions including Senior Vice President and Chief Medical Officer of Oncology at Geron Corporation, Vice President of Medical Affairs at Onyx as well as Millennium Pharmaceuticals, and has held Medical Director level positions at Bristol-Myers Squibb and Roche Laboratories. Dr. Benedetti graduated from Brown University, where he also went on to receive his medical degree in 1990. After finishing his Internal Medicine residency at Strong-Memorial Hospital in Rochester, NY, he went on to complete a Medical Oncology/Hematology fellowship at the Memorial Sloan-Kettering Cancer Center in New York City, where he subsequently worked as an Attending Physician for the Gastrointestinal Oncology Service.
Teruhiro Utsugi, Ph.D.
Executive Director
Discovery & Preclinical Research Division
Strategic Early Development Planning Dept.,
Business Development
Intellectual Property, Legal Affairs
Taiho Pharmaceutical Co., Ltd.
Dr. Teruhiro Utsugi joined Taiho in 1991 and has held several positions in the R&D and Business Development Divisions. Prior to this, he spent 4 years as a scientist at SmithKline French Laboratories and M.D. Anderson Cancer Center in the U.S., and brought with him a vast knowledge in product research. Dr. Utsugi received his bachelor’s and master’s degrees from the University of Nagasaki, and went on to receive his doctorate in Nutrition Science from the University of Tokushima in 1987.

U.S. Leadership Team

Taiho Oncology’s U.S. leadership team brings strong leadership to the North American marketplace, while staying true to Taiho’s legacy of developing the highest quality pharmaceuticals that improve the lives of people everywhere.

Tim Whitten
President & CEO
Taiho Oncology, Inc.
Timothy Whitten joined Taiho Oncology in 2013 as the Senior Vice President and CCO to build the first commercial business unit for Taiho in the West and to oversee the company’s commercial functions. In 2017, Mr. Whitten was promoted to Senior Vice President and COO, adding human resources and operations of Taiho Pharma Canada, Inc. to his responsibilities. On January 1, 2018, Mr. Whitten was promoted to President, Taiho Oncology, Inc., and given a position on the Taiho Oncology Board of Directors as he assumed leadership responsibility for corporate, commercial and clinical development-related functions at Taiho Oncology. In addition, Mr. Whitten serves as President of Taiho Pharma Canada and holds a seat on the Taiho Pharma Canada Board, as well as having operational responsibility for Taiho Pharma Europe, Ltd. As of April 1, 2018, Mr. Whitten has been named President and CEO of Taiho Oncology, reporting directly to Masayuki Kobayashi, President and Representative Director Pharmaceutical Co., Ltd., headquartered in Tokyo, Japan, following Eric Benn’s retirement as CEO, Taiho Oncology, Inc. Prior to joining Taiho Oncology, Inc., Mr. Whitten served as President and CEO of Transave/lnsmed from 2006 to 2012. During this time, he guided the company’s lead product from the preclinical stage into a global phase 3 program. In 2010, Mr. Whitten took the private company, Transave, into the public marketplace via a business combination with lnsmed. From 2001 to 2006, Mr. Whitten was employed by Pharmacyclics, where he served in various roles, including Senior Vice President, Marketing & Sales, and Business Development. Mr. Whitten spent 17 years at Bristol-Myers Squibb, where he served in various sales, marketing, and strategic planning roles, including Vice President, Marketing, for the U.S. Oncology and Immunology franchise and Vice President, Global Marketing, Oncology, Immunology, and Pulmonary Diseases. Among his accomplishments, including several product launches, he directed the successful introduction of Taxol® into the U.S. oncology market. Mr. Whitten graduated from West Virginia University with a Bachelor of Science in Pharmacy and from the University of Virginia with a Master of Business Administration.
Martin J. Birkhofer, M.D.
Senior Vice President and Chief Medical Officer
Taiho Oncology, Inc.
Dr. Martin J. Birkhofer was appointed Taiho Oncology Inc.’s Senior Vice President and Chief Medical Officer on June 19, 2017. As Chief Medical Officer Dr. Birkhofer has responsibility for the Taiho Oncology Development organization, driving clinical development of our pipeline assets in all geographies outside of Asia. In addition his responsibilities include, Regulatory Affairs, Medical Affairs and Pharmacovigilance. Dr. Birkhofer is a Medical Oncologist and accomplished leader in the oncology biopharmaceutical industry with over 28 years of experience encompassing all phases of global clinical research & development with both small molecules and biologics. He spent the bulk of his career at Bristol-Myers Squibb where he held a variety of senior positions in Clinical Development, Clinical Pharmacology, Medical Affairs and Business Development. In addition, he has served as the Chief Medical Officer of a major contract research organization, inVentiv Health Clinical and of several privately held, venture backed biotech companies. Dr. Birkhofer received his M.D. from New York Medical College, Valhalla, New York and then post graduate medical training in Internal Medicine from St. Elizabeth’s Hospital of Boston, Boston, MA and in Hematology/Oncology from Columbia University College of Physicians and Surgeons, NY, NY.
Michael Schick
Senior Vice President, Commercial
Taiho Oncology, Inc.
Michael Schick was promoted to Sr. Vice President, Commercial in April, 2017, taking on responsibility for Market Access and Market Research to create a positive synergy with improved efficiency in Commercial operations and utilization of resources. In May, 2016, Michael was promoted to Sr. Vice President, Sales and Marketing, leading the entire sales, marketing, and sales operations teams. Michael Schick joined Taiho Oncology, Inc. as Vice President, Sales in Marketing in July 2013. Prior to joining the company, Mr. Schick was a self-employed consultant to the pharmaceutical industry from January 2013 to June 2013. Before that, he served various sales and marketing leadership roles at Allos Therapeutics, including Vice President, Sales and Marketing and Vice President of Marketing from July 2009 to October 2012. While at Allos, Mr. Schick was a member of the executive management team that transformed the organization from a development stage biotech to a commercial stage pharmaceutical company. Prior to that, he served as Associate Vice President, Oncology Marketing at ImClone Systems from October 2007 to July 2009, where he was responsible for the Erbitux® (cetuximab injection) franchise across multiple indications. Prior to that, from February 2006 to October 2007, Mr. Schick was Executive Director, Oncology Global Marketing at Amgen Inc., where he was responsible for global marketing activities for Neulasta® (pegfilgrastim) and Aranesp® (darbepoetin alfa injection). From November 2004 to January 2006, Mr. Schick served as Director, Marketing at Pharmacyclics, Inc. Before that, he served in a variety of commercial roles at Bristol-Myers Squibb, including sales, strategic planning, and product management focused on multiple oncology brands, including Taxol® (paclitaxel injection) and Paraplatin® (carboplatin for injection), and the launch of Erbitux for metastatic colorectal cancer. Mr. Schick earned his B.A. from Villanova University.
Hiroshi Ambe
Sr. Vice President, Scientific Services
Taiho Oncology, Inc.
Hiroshi Ambe was appointed Taiho Oncology Inc.’s Senior Vice President, Scientific Services in December 2017. As Senior Vice President, Scientific Services, Mr. Ambe, reporting directly to the CMO, is responsible for leadership of the following key functional areas: Drug Metabolism and Pharmacokinetics, Biomarkers, Biostatistics, Medical Writing, and Clinical Research. Since 1986, Mr. Ambe has held numerous positions with increasing responsibility within Taiho Pharmaceutical, Co. Ltd. in Tokyo, Japan, including roles in clinical development, medical affairs, data management & biostatistics, portfolio management, and business development. This is Mr. Ambe’s third time leading a function at Taiho Oncology, Inc. Previously, he was Director, Clinical Research from 2002-2005 and VP, Clinical Research from 2010-2015. During Mr. Ambe’s tenure at Taiho, he has had experience in regulatory submissions and successful approvals obtained from health agencies in Japan, EU, USA and China. Mr. Ambe received a Bachelor’s degree in Agriculture from Kyoto University, Kyoto, Japan.
Kazuhiko Okamoto
Vice President, Finance
Taiho Oncology, Inc.
Kazuhiko Okamoto was appointed our Vice President, Finance in January 2016, following 5 years as Secretary & Treasurer of Taiho Pharma USA. Prior to joining Taiho, he worked for Infineon Technologies AG, a global German semiconductor company from 2000 to 2009, of which he took a several critically important positions in the functional areas of Finance, Sales and Strategic Marketing at the German HQ in Munich from 2003 to 2009. He also worked for OKI Electric Industry, a Japanese semiconductor company from 1996 to 2000 with Sales responsibility for the European and US markets. Mr. Okamoto is a Certified Public Accountant for the state of Washington. He earned a Bachelor of Commerce degree from Doshisha University in Kyoto in Japan.

Success!

Job description sent to

Success!

Event sent to

Success!

News Release sent to